2024 SPEAKERS
Michael Abramoff, MD, PhD
University of Iowa School of Medicine
Natalie Afshari, MD, FACS
UC San Diego Shiley Eye Institute
Mayssa Attar, PhD
Bausch + Lomb
Sharon Bakalash MD, PhD
Astellas Ophthalmics
Mark R. Barakat, MD
Retina Macula Institute of Arizona / Spectra Eye Institute / University of Arizona College of Medicine
Susan Benton, MBA
Tarsier Pharma
Anna Chen
Frazier Life Sciences
Liane Clamen, MD
Adaptilens
Kirstie R. Cole
Bausch + Lomb
Karl Csaky, MD, PhD
Retina Foundation of the Southwest
Emmett T. Cunningham Jr., MD, PhD, MPH
Eyconis / HealthQuest Capital Management
Anupam Dalal, MD
Acuta Capital Partners
Eugene de Juan, MD
UCSF Department of Ophthalmology
Pravin U. Dugel, MD
Ocular Therapeutix
David Esposito
ONL Therapeutics
Jeffrey Friedman, MD, PhD
Friedman Bioventure
Alexander Gebauer, MD, PhD
Galimedix Therapeutics
Andrew Gitkin
Leerink Partners
Jeffrey Goldberg, MD, PhD
Emmecell
Adrienne Graves, PhD
Glaucoma 360
Amy Hopkin, PhD
AbbVie
Jason Jun
Citi
Joe Markson, PhD
Novo Holdings
Mike Mbagwu, MD
Astellas Pharma
Morgan Micheletti, MD, FACS
Berkeley Eye Center
Patrick Mooney
SpyGlass Pharma
James C. Murray
ExSight Ventures
David Myung, MD, PhD
Byers Eye Institute at Stanford University School of Medicine
Tomas Navratil, PhD
Glaukos
Tomo Oe, PhD
Astellas Pharma
Susan Orr, OD
Claris Bio
Ram Palanki, PharmD
REGENXBIO
Jai G. Parekh, MD, MBA
Nordic Pharma Eye Care
Stephen Poor
Apellis Pharmaceuticals
Firas Rahhal, MD
ExSight Ventures & Retina Vitreous Associates Medical Group
Robert Rothman, MD
InFocus Capital Partners / OCLI/Glaucoma Consultants of Long Island
Zach Scheiner, PhD
RA Capital Management
Eric Schlumpf
Stuart Therapeutics
Riad Sherif, MD
Oculis
Shannon Spock, MPH
Alcon
Jessica Steen, OD, FAAO
Nova Southeastern University
Andrew Stewart
Bausch + Lomb
Cari Stone
Elios Vision
Cameron Taylor
BofA Securities | Life Sciences
Tracy Valorie, MBA
TMV Associates